(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 60MM | - |
Operating Income | -24MM | -52% |
Operating Expenses | 84MM | +51% |
Net Income | -18.9MM | -58% |
R&D | 69.6MM | +72% |
G&A | 14.5MM | -4% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The company now has a chance to get its lead program out the door a bit sooner.
Editas Medicine Inc (NASDAQ:EDIT), a leading genome editing company, focuses on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world.
The biotech has bounced back some in the past year.
The clinical-stage genome editing company dropped a couple of important announcements for shareholders.
Editas Medicine, Inc. ( NASDAQ:EDIT ) just released its latest full-year results and things are looking bullish...
Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript February 28, 2024 Editas Medicine, Inc. beats earnings expectations. Reported EPS is $-0.23, expectations were $-0.52. EDIT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to Editas […]
Editas (EDIT) reports better-than-expected fourth-quarter 2023 results as both earnings and revenues beat estimates, driven by collaboration revenues received from Vertex. The stock gains 25%.
Q4 2023 Editas Medicine Inc Earnings Call
Editas (EDIT) delivered earnings and revenue surprises of 55.77% and 347.63%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?